Research director has big plans for Lundbeck's new focus area
Lundbeck's new Head of Research and Development Johan Luthman has plans that go beyond commercializing Alder Biopharmaceuticals' main asset against migraine. He wants Lundbeck to gain a strong foothold in the migraine market.
The migraine candidate eptinezumab was the absolute center of attention when Danish drug group Lundbeck announced the plans to acquire US-based Alder Biopharmaceuticals last week.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
